Elevated levels of TWEAK in skeletal muscle promote visceral obesity, insulin resistance, and metabolic dysfunction

FASEB Journal

Volumn 29, Issue 3, 2015, Pages 988-1002

  Sato, Shuichi ^a   Ogura, Yuji ^a   Tajrishi, Marjan M ^a   Kumar, Ashok ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

AMPK; Fn14; GLUT4; PGC 1 ; Type 2 diabetes

Indexed keywords

CD11B ANTIGEN; CD68 ANTIGEN; CYTOKINE; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE 3BETA; HEXOKINASE; HEXOKINASE 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 15; MESSENGER RNA; MYOCYTE ENHANCER FACTOR 2; MYOD PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS LIKE WEAK INDUCER OF APOPTOSIS CYTOKINE; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; KLF15 PROTEIN, MOUSE; SLC2A4 PROTEIN, MOUSE; TNFSF12 PROTEIN, MOUSE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; CELL SHAPE; CELL SIZE; CONTROLLED STUDY; DOWN REGULATION; ENERGY BALANCE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; EPIDIDYMIS FAT; EXERCISE; EXERCISE TOLERANCE; FAT MASS; GENE ACTIVATION; GENE CONTROL; GENE LOCUS; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; GLYCOGEN ANALYSIS; GLYCOGEN SYNTHESIS; HYPERGLYCEMIA; HYPERTROPHY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LIPID METABOLISM; LIPID STORAGE; LUNG GAS EXCHANGE; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; MOUSE; MUSCLE MASS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WEIGHT GAIN; ANIMAL; C57BL MOUSE; CELL CULTURE; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; OBESITY, ABDOMINAL; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; TRANSGENIC MOUSE; WESTERN BLOTTING;

MUS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; DNA-BINDING PROTEINS; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORTER TYPE 4; HUMANS; INSULIN RESISTANCE; MALE; MEF2 TRANSCRIPTION FACTORS; MICE; MICE, INBRED C57BL; MICE, OBESE; MICE, TRANSGENIC; MUSCLE, SKELETAL; OBESITY, ABDOMINAL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTORS;

EID: 84937440550     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-260703     Document Type: Article

References (65)

1. Thiebaud, D., Jacot, E., DeFronzo, R. A., Maeder, E., Jequier, E., and Felber, J. P. (1982) The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man. Diabetes 31, 957-963
2. Defronzo, R. A. (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58, 773-795
3. Warram, J. H., Martin, B. C., Krolewski, A. S., Soeldner, J. S., and Kahn, C. R. (1990) Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann. Intern. Med. 113, 909-915
4. DeFronzo, R. A., Jacot, E., Jequier, E., Maeder, E., Wahren, J., and Felber, J. P. (1981) The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30, 1000-1007
5. DeFronzo, R. A., and Tripathy, D. (2009) Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32 (Suppl 2), S157-S163
6. Kalupahana, N. S., Moustaid-Moussa, N., and Claycombe, K. J. (2012) Immunity as a link between obesity and insulin resistance. Mol. Aspects Med. 33, 26-34
7. Ng, Y., Ramm, G., Lopez, J. A., and James, D. E. (2008) Rapid activation of Akt2 is sufficient to stimulate GLUT4 translocation in 3T3-L1 adipocytes. Cell Metab. 7, 348-356
8. Krook, A., Björnholm, M., Galuska, D., Jiang, X. J., Fahlman, R., Myers, M. G., Jr., Wallberg-Henriksson, H., and Zierath, J. R. (2000) Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 49, 284-292
9. Cusi, K., Maezono, K., Osman, A., Pendergrass, M., Patti, M. E., Pratipanawatr, T., DeFronzo, R. A., Kahn, C. R., and Mandarino, L. J. (2000) Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J. Clin. Invest. 105, 311-320
10. Bouzakri, K., Roques, M., Gual, P., Espinosa, S., Guebre-Egziabher, F., Riou, J. P., Laville, M., Le Marchand-Brustel, Y., Tanti, J. F., and Vidal, H. (2003) Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. Diabetes 52, 1319-1325
11. Ruderman, N. B., Carling, D., Prentki, M., and Cacicedo, J. M. (2013) AMPK, insulin resistance, and the metabolic syndrome. J. Clin. Invest. 123, 2764-2772
12. Garvey, W. T., Maianu, L., Hancock, J. A., Golichowski, A. M., and Baron, A. (1992) Gene expression of GLUT4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. Diabetes 41, 465-475
13. Handberg, A., Vaag, A., Damsbo, P., Beck-Nielsen, H., and Vinten, J. (1990) Expression of insulin regulatable glucose transporters in skeletal muscle from type 2 (non-insulin-dependent) diabetic patients. Diabetologia 33, 625-627
14. Leturque, A., Loizeau, M., Vaulont, S., Salminen, M., and Girard, J. (1996) Improvement of insulin action in diabetic transgenic mice selectively overexpressing GLUT4 in skeletal muscle. Diabetes 45, 23-27
15. Ren, J. M., Marshall, B. A., Mueckler, M. M., McCaleb, M., Amatruda, J. M., and Shulman, G. I. (1995) Overexpression of Glut4 protein in muscle increases basal and insulin-stimulated whole body glucose disposal in conscious mice. J. Clin. Invest. 95, 429-432
16. Atkinson, B. J., Griesel, B. A., King, C. D., Josey, M. A., and Olson, A. L. (2013) Moderate GLUT4 overexpression improves insulin sensitivity and fasting triglyceridemia in high-fat diet-fed transgenic mice. Diabetes 62, 2249-2258
17. Zisman, A., Peroni, O. D., Abel, E. D., Michael, M. D., Mauvais-Jarvis, F., Lowell, B. B., Wojtaszewski, J. F., Hirshman, M. F., Virkamaki, A., Goodyear, L. J., Kahn, C. R., and Kahn, B. B. (2000) Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat. Med. 6, 924-928
18. Koranyi, L. I., Bourey, R. E., Vuorinen-Markkola, H., Koivisto, V. A., Mueckler, M., Permutt, M. A., and Yki-Järvinen, H. (1991) Level of skeletal muscle glucose transporter protein correlates with insulin-stimulated whole body glucose disposal in man. Diabetologia 34, 763-765
19. Christ-Roberts, C. Y., Pratipanawatr, T., Pratipanawatr, W., Berria, R., Belfort, R., Kashyap, S., and Mandarino, L. J. (2004) Exercise training increases glycogen synthase activity and GLUT4 expression but not insulin signaling in overweight nondiabetic and type 2 diabetic subjects. Metabolism 53, 1233-1242
20. Nieto-Vazquez, I., Fernández-Veledo, S., Krämer, D. K., Vila-Bedmar, R., Garcia-Guerra, L., and Lorenzo, M. (2008) Insulin resistance associated to obesity: the link TNF-alpha. Arch. Physiol. Biochem. 114, 183-194
21. Mingrone, G., Rosa, G., Di Rocco, P., Manco, M., Capristo, E., Castagneto, M., Vettor, R., Gasbarrini, G., and Greco, A. V. (2002) Skeletal muscle triglycerides lowering is associated with net improvement of insulin sensitivity, TNF-alpha reduction and GLUT4 expression enhancement. Int. J. Obes. Relat. Metab. Disord. 26, 1165-1172
22. Hotamisligil, G. S., Shargill, N. S., and Spiegelman, B. M. (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87-91
23. Uysal, K. T., Wiesbrock, S. M., Marino, M. W., and Hotamisligil, G. S. (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389, 610-614
24. Gregor, M. F., and Hotamisligil, G. S. (2011) Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29, 415-445
25. Shoelson, S. E., Lee, J., and Goldfine, A. B. (2006) Inflammation and insulin resistance. J. Clin. Invest. 116, 1793-1801
26. Ofei, F., Hurel, S., Newkirk, J., Sopwith, M., and Taylor, R. (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45, 881-885
27. Tajrishi, M. M., Zheng, T. S., Burkly, L. C., and Kumar, A. (2014) The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease. Cytokine Growth Factor Rev. 25, 215-225
28. Mittal, A., Bhatnagar, S., Kumar, A., Lach-Trifilieff, E., Wauters, S., Li, H., Makonchuk, D. Y., Glass, D. J., and Kumar, A. (2010) The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J. Cell Biol. 188, 833-849
29. Paul, P. K., Bhatnagar, S., Mishra, V., Srivastava, S., Darnay, B. G., Choi, Y., and Kumar, A. (2012) The E3 ubiquitin ligase TRAF6 intercedes in starvation-induced skeletal muscle atrophy through multiple mechanisms. Mol. Cell. Biol. 32, 1248-1259
30. Tajrishi, M. M., Sato, S., Shin, J., Zheng, T. S., Burkly, L. C., and Kumar, A. (2014) The TWEAK-Fn14 dyad is involved in age-associated pathological changes in skeletal muscle. Biochem. Biophys. Res. Commun. 446, 1219-1224
31. Sato, S., Ogura, Y., Mishra, V., Shin, J., Bhatnagar, S., Hill, B. G., and Kumar, A. (2013) TWEAK promotes exercise intolerance by decreasing skeletal muscle oxidative phosphorylation capacity. Skelet Muscle 3, 18
32. Dogra, C., Changotra, H., Wedhas, N., Qin, X., Wergedal, J. E., and Kumar, A. (2007) TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. 21, 1857-1869
33. Tai, M. M. (1994) A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 17, 152-154
34. Kahn, B. B., and Flier, J. S. (2000) Obesity and insulin resistance. J. Clin. Invest. 106, 473-481
35. Hindi, S. M., Mishra, V., Bhatnagar, S., Tajrishi, M. M., Ogura, Y., Yan, Z., Burkly, L. C., Zheng, T. S., and Kumar, A. (2014) Regulatory circuitry of TWEAK-Fn14 system and PGC-1α in skeletal muscle atrophy program. FASEB J. 28, 1398-1411
36. Woodgett, J. R. (1991) A common denominator linking glycogen metabolism, nuclear oncogenes and development. Trends Biochem. Sci. 16, 177-181
37. Sutherland, C., Leighton, I. A., and Cohen, P. (1993) Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J. 296, 15-19
38. Itani, S. I., Saha, A. K., Kurowski, T. G., Coffin, H. R., Tornheim, K., and Ruderman, N. B. (2003) Glucose autoregulates its uptake in skeletal muscle: involvement of AMP-activated protein kinase. Diabetes 52, 1635-1640
39. Walker, P. S., Ramlal, T., Sarabia, V., Koivisto, U. M., Bilan, P. J., Pessin, J. E., and Klip, A. (1990) Glucose transport activity in L6 muscle cells is regulated by the coordinate control of subcellular glucose transporter distribution, biosynthesis, and mRNA transcription. J. Biol. Chem. 265, 1516-1523
40. McGee, S. L., van Denderen, B. J., Howlett, K. F., Mollica, J., Schertzer, J. D., Kemp, B. E., and Hargreaves, M. (2008) AMP-activated protein kinase regulates GLUT4 transcription by phosphorylating histone deacetylase 5. Diabetes 57, 860-867
41. Sakoda, H., Ogihara, T., Anai, M., Fujishiro, M., Ono, H., Onishi, Y., Katagiri, H., Abe, M., Fukushima, Y., Shojima, N., Inukai, K., Kikuchi, M., Oka, Y., and Asano, T. (2002) Activation of AMPK is essential for AICAR-induced glucose uptake by skeletal muscle but not adipocytes. Am. J. Physiol. Endocrinol. Metab. 282, E1239-E1244
42. Crunkhorn, S., Dearie, F., Mantzoros, C., Gami, H., da Silva, W. S., Espinoza, D., Faucette, R., Barry, K., Bianco, A. C., and Patti, M. E. (2007) Peroxisome proliferator activator receptor gamma coactivator-1 expression is reduced in obesity: potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation. J. Biol. Chem. 282, 15439-15450
43. Kruszynska, Y. T., Mulford, M. I., Baloga, J., Yu, J. G., and Olefsky, J. M. (1998) Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Diabetes 47, 1107-1113
44. Jäger, S., Handschin, C., St-Pierre, J., and Spiegelman, B. M. (2007) AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl. Acad. Sci. USA 104, 12017-12022
45. Im, S. S., Kwon, S. K., Kim, T. H., Kim, H. I., and Ahn, Y. H. (2007) Regulation of glucose transporter type 4 isoform gene expression in muscle and adipocytes. IUBMB Life 59, 134-145
46. Bogan, J. S. (2012) Regulation of glucose transporter translocation in health and diabetes. Annu. Rev. Biochem. 81, 507-532
47. Feng, F., Wang, L., Albanese, N., Holmes, A., and Xia, P. (2008) Tumor necrosis factor-like weak inducer of apoptosis attenuates the action of insulin in hepatocytes. Endocrinology 149, 1505-1513
48. Chacón, M. R., Richart, C., Gómez, J. M., Megía, A., Vilarrasa, N., Fernández-Real, J. M., García-España, A., Miranda, M., Masdevall, C., Ricard, W., Caubet, E., Soler, J., and Vendrell, J. (2006) Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity. Cytokine 33, 129-137
49. Bennett, G., Strissel, K. J., DeFuria, J., Wang, J., Wu, D., Burkly, L. C., and Obin, M. S. (2014) Deletion of TNF-like weak inducer of apoptosis (TWEAK) protects mice from adipose and systemic impacts of severe obesity. Obesity (Silver Spring) 22, 1485-1494
50. Tajrishi, M. M., Shin, J., Hetman, M., and Kumar, A. (2014) DNA methyltransferase 3a and mitogen-activated protein kinase signaling regulate the expression of fibroblast growth factor-inducible 14 (Fn14) during denervation-induced skeletal muscle atrophy. J. Biol. Chem. 289, 19985-19999
51. Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw III, E. B., Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., and Birnbaum, M. J. (2001) Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292, 1728-1731
52. Mittal, A., Bhatnagar, S., Kumar, A., Paul, P. K., Kuang, S., and Kumar, A. (2010) Genetic ablation of TWEAK augments regeneration and post-injury growth of skeletal muscle in mice. Am. J. Pathol. 177, 1732-1742
53. Steinberg, G. R., Michell, B. J., van Denderen, B. J., Watt, M. J., Carey, A. L., Fam, B. C., Andrikopoulos, S., Proietto, J., Görgün, C. Z., Carling, D., Hotamisligil, G. S., Febbraio, M. A., Kay, T. W., and Kemp, B. E. (2006) Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab. 4, 465-474
54. Suzuki, T., Bridges, D., Nakada, D., Skiniotis, G., Morrison, S. J., Lin, J. D., Saltiel, A. R., and Inoki, K. (2013) Inhibition of AMPK catabolic action by GSK3. Mol. Cell 50, 407-419
55. Braithwaite, S. S., Palazuk, B., Colca, J. R., Edwards III, C. W., and Hofmann, C. (1995) Reduced expression of hexokinase II in insulin-resistant diabetes. Diabetes 44, 43-48
56. Frank, S. K., and Fromm, H. J. (1986) Effect of streptozotocin-induced diabetes and insulin treatment on the synthesis of hexokinase II in the skeletal muscle of the rat. Arch. Biochem. Biophys. 249, 61-69
57. Pendergrass, M., Koval, J., Vogt, C., Yki-Jarvinen, H., Iozzo, P., Pipek, R., Ardehali, H., Printz, R., Granner, D., DeFronzo, R. A., and Mandarino, L. J. (1998) Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes 47, 387-394
58. Højlund, K., Birk, J. B., Klein, D. K., Levin, K., Rose, A. J., Hansen, B. F., Nielsen, J. N., Beck-Nielsen, H., and Wojtaszewski, J. F. (2009) Dysregulation of glycogen synthase COOH- and NH2-terminal phosphorylation by insulin in obesity and type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 94, 4547-4556
59. Fueger, P. T., Lee-Young, R. S., Shearer, J., Bracy, D. P., Heikkinen, S., Laakso, M., Rottman, J. N., and Wasserman, D. H. (2007) Phosphorylation barriers to skeletal and cardiac muscle glucose uptakes in high-fat fed mice: studies in mice with a 50% reduction of hexokinase II. Diabetes 56, 2476-2484
60. Chang, P. Y., Jensen, J., Printz, R. L., Granner, D. K., Ivy, J. L., and Moller, D. E. (1996) Overexpression of hexokinase II in transgenic mice. Evidence that increased phosphorylation augments muscle glucose uptake. J. Biol. Chem. 271, 14834-14839
61. Bouskila, M., Hirshman, M. F., Jensen, J., Goodyear, L. J., and Sakamoto, K. (2008) Insulin promotes glycogen synthesis in the absence of GSK3 phosphorylation in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 294, E28-E35
62. Jensen, J., and Lai, Y. C. (2009) Regulation of muscle glycogen synthase phosphorylation and kinetic properties by insulin, exercise, adrenaline and role in insulin resistance. Arch. Physiol. Biochem. 115, 13-21
63. Liu, M. L., Olson, A. L., Edgington, N. P., Moye-Rowley, W. S., and Pessin, J. E. (1994) Myocyte enhancer factor 2 (MEF2) binding site is essential for C2C12 myotube-specific expression of the rat GLUT4/muscle-adipose facilitative glucose transporter gene. J. Biol. Chem. 269, 28514-28521
64. Michael, L. F., Wu, Z., Cheatham, R. B., Puigserver, P., Adelmant, G., Lehman, J. J., Kelly, D. P., and Spiegelman, B. M. (2001) Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc. Natl. Acad. Sci. USA 98, 3820-3825
65. McGee, S. L., and Hargreaves, M. (2006) Exercise and skeletal muscle glucose transporter 4 expression: molecular mechanisms. Clin. Exp. Pharmacol. Physiol. 33, 395-399